The Analyst · 2019 · 34 citations · 40 references
PharmacyPharmacokineticsPharmacologyBioavailabilityDrug DeliveryNanoparticle Drug DeliveryNanomaterials For Drug DeliveryNanomedicineNanoparticle DesignNanoparticle FormulationsNanoparticle-based BioavailabilityOral NanocarriersDrug Delivery NanocarriersLow SolubilityNanoparticle-mediated Bioavailability EnhancementOral Nanoparticle BioavailabilityPharmacokinetic EnhancementPharmacokinetics Of NanocarriersSolubilitySystemic Drug Delivery
). The systemic exposure of LbL NPs was compared to the respective nanoformulation without LbL coatings (RSV nanocores) and the free RSV suspension. The results demonstrated that both LbL NPs and RSV nanocores significantly enhanced, respectively, 1.76-fold and 2.74-fold the systemic exposure of RSV compared to the free RSV suspension, emphasizing their biopharmaceutical advantage. Surprisingly, besides the modified drug release potential of the LbL NPs, these exhibited a slightly lower systemic exposure (0.36-fold) in comparison with non-LbL modified RSV nanocores. These results were justified only by the electrostatic interactions composition of the LbL shell composition, requiring further research towards the application of stronger interactions. For this study, due to the key role of the bioanalytical method in the in vivo data acquisition, a rapid, selective, and sensitive HPLC-DAD method has been successfully optimized and fully validated to confidently quantify RSV levels in the rat plasma matrix, together with the optimization of the sample preparation procedure. Moreover, the chemical stability of RSV was evaluated for 24 h in simulated gastric and intestinal fluids with enzymes. Overall, our findings suggest that LbL NPs should be given great attention, representing a potential drug delivery system for RSV in view of the application of RSV not solely as a supplement but also as a therapeutic drug.
40
Bioanalytical Method Validation—A Revisit with a Decade of Progress
Vinod P. Shah, Kamal K. Midha, John W. A. Findlay et al. · Pharmaceutical Research · 2000 · 1.6K citations